Forest Pharmaceuticals was sentenced last week to pay $150 million in criminal fines and an additional $14 million in forfeiture, pursuant to a plea agreement entered in September 2010 related to off-label marketing of Celexa, Levathroid, and Lexapro, according to DoJ.  FraudBlawg previously reported the plea agreement, here. In addition to the criminal fine and forfeiture, Forest paid $149 million pursuant to a qui tam whistleblower claim under the False Claims Act. The whistleblowers who alerted DoJ to the fraud received an award of $14 million.

If you have credible, first-hand knowledge of fraud against the government, you may be entitled to a substantial reward. To report Medicare fraud or other False Claims Act violations, contact Frohsin & Barger.